Age-associated metabolic dysregulation in bone marrow-derived macrophages stimulated with lipopolysaccharide

Fan Fei$^{1,2}$, Keith M. Lee$^{2}$, Brian E. McCarry$^{1}$ & Dawn M. E. Bowdish$^{2}$

Macrophages are major contributors to age-associated inflammation. Metabolic processes such as oxidative phosphorylation, glycolysis and the urea cycle regulate inflammatory responses by macrophages. Metabolic profiles change with age; therefore, we hypothesized that dysregulation of metabolic processes could contribute to macrophage hyporesponsiveness to LPS. We examined the intracellular metabolome of bone marrow-derived macrophages from young (6–8 wk) and old (18–22 mo) mice following lipopolysaccharide (LPS) stimulation and tolerance. We discovered known and novel metabolites that were associated with the LPS response of macrophages from young mice, which were not inducible in macrophages from old mice. Macrophages from old mice were largely non-responsive towards LPS stimulation, and we did not observe a shift from oxidative phosphorylation to glycolysis. The critical regulatory metabolites succinate, $\gamma$-aminobutyric acid, arginine, ornithine and adenosine were increased in LPS-stimulated macrophages from young mice, but not macrophages from old mice. A shift between glycolysis and oxidative phosphorylation was not observed during LPS tolerance in macrophages from either young or old mice. Metabolic bottlenecks may be one of the mechanisms that contribute to the dysregulation of LPS responses with age.

Inflammation is an evolutionarily conserved response to infection and tissue injury, which triggers a complex cascade of metabolic and genomic responses. Both innate and adaptive immune function declines with age, and this contributes to decreased vaccine responses and increased susceptibility to sepsis and inflammatory diseases. Franceschi et al. proposed that macrophages play a central role in producing age-associated inflammation, which ultimately impairs the immune response. Macrophages are heterogeneous tissue-resident sentinel cells that are derived from hematopoietic progenitors. They initiate inflammatory responses towards microbial pathogens and repair damaged tissues by responding to their local cytokine environment and adapting to either pro-inflammatory (M1) or anti-inflammatory (M2) phenotypes. With age, macrophage functions, including phagocytosis, wound healing and polarization, are impaired.

Bacterial lipopolysaccharide (LPS) is a potent inflammatory stimulant that is often used to study macrophage function. Upon repeated challenge with LPS, macrophages become refractory to stimulation with LPS and this “LPS tolerance” can persist for 24–48 hrs after initial stimulation. LPS tolerance is an essential immune-homeostatic response that protects against hyper-inflammatory responses during persistent infection, but may also contribute to septic and non-infectious systemic inflammatory response syndrome (SIRS) in humans. Peritoneal macrophages from young mice develop LPS tolerance more effectively than macrophages from old mice. Whether failure to control inflammation due to chronic LPS exposure contributes to increased susceptibility to inflammatory diseases in old age is not known.

Inflammatory responses of macrophages can be regulated by intracellular and extracellular levels of metabolites. It is known that upon LPS stimulation, macrophages switch from oxidative phosphorylation to glycolysis as their primary energy source to sustain the increased energy demand during inflammation. Enhanced glycolytic function is measured by increased levels of intra- and extra-cellular lactate. Specific transcriptional responses
promoting inflammation have been shown to be regulated by metabolites such as succinate and γ-aminobutyric acid. Additionally, M1/M2 polarization is regulated by increasing levels of urea cycle intermediates such as arginine, ornithine, citrulline. Increased levels of adenosine as a result of inflammation can regulate inflammatory responses and are protective against tissue damage. Metabolic changes have been noted in mice and humans as a result of aging. Whether metabolic dysregulation can contribute to macrophage dysfunction with age is not known.

Here, for the first time, we identified age-specific metabolic dysregulation of LPS responses in bone marrow-derived macrophages. Additionally, we quantified the metabolic changes during LPS tolerance in both young and old macrophages. We discovered novel metabolites that are associated with LPS stimulation. We have found metabolic reprogramming of oxidative phosphorylation to glycolysis was suppressed in LPS stimulated macrophages from old mice. In addition, arginine metabolism, which is vital for macrophage polarization, was also impaired in old macrophages. Our data indicate a possible metabolic bottleneck that prevents energy intensive inflammatory responses in old macrophages.

Results

In order to quantitate differences in macrophage metabolism during LPS stimulation and LPS tolerance, bone marrow derived macrophages from young and old mice were analyzed using both comprehensive and targeted metabolomic strategies (Fig. 1). Liquid chromatography-mass spectrometry (LC-MS) was used to create a comprehensive metabolomic profile, which was composed of 2125 metabolite features, of which 57 polar metabolites and 64 phospholipids were identified. Gas chromatography (GC)-MS was used for targeted metabolomic analysis, which included 25 intermediates in glycolysis, the citric acid cycle (TCA), the aspartate-argininosuccinate shunt, the γ-aminobutyric acid (GABA) shunt and the urea cycle pathways (Table S1).

Comprehensive analysis reveals novel metabolites associated with LPS responses. The metabolome of bone marrow derived macrophages from young mice were analyzed and compared at 0, 4 and 16 hr of LPS stimulation. To ensure any metabolic changes only resulted from LPS stimulation and were not a result of the 22 hr incubation, we compared the metabolic profiles of unstimulated macrophages at t = 0 hr and t = 22 hrs. Less than 1.3% of the metabolic features showed any significant change over the 22 hr period. Significant metabolic changes were observed for LPS stimulated macrophages after 4 hrs of stimulation, and a more dramatic change was noted after 16 hrs of LPS stimulation (Fig. 2A). The metabolite features from young macrophages that were differentially expressed after 4 hrs of LPS stimulation were compared to the unstimulated control 4.5% (96/2125) (Fig. 2B). After 16 hrs of LPS stimulation, over half of the metabolic features (1081/2125) were significantly altered in the young macrophages. Of the differentially expressed features, 27.2% (579/2125) showed increased expression and 23.6% (502/2125) features were reduced compared to the unstimulated control. Metabolites that were found to increase in macrophages of young mice after 16 hrs of LPS stimulation included adenosine, adenosine, ornithine, arginine (Fig. 3A–D), pantothenic acid, uridine diphosphate N-acetylgalactosamine (UDP-GlcNAc), N-acetyl-phenylalanine, taurine, hypotaurine, UDP-glucose (UDP-G), glucosamine-6-phosphate (GlcN6P), methyl-malic acid, lysisine, proline, glutamine, phosphatidylylycerols (PGs), phosphatidylethanolamine (PEs) and phosphatidyglycerols (PCs). N-acetyl glutamic acid and N-acetyl-aspartic acid were reduced after 16 hrs of LPS exposure. Most metabolic features remained unidentified. The comprehensive metabolomic approach allows the discovery of novel metabolites associated to macrophage LPS responses (normalized levels of metabolites are included in the supplementary material 2).

Macrophage metabolism in response to LPS decreases with age. The metabolomes of bone marrow derived macrophages from both young and old mice were analyzed and compared prior to LPS stimulation (t = 0 hr), and after 4 and 16 hrs of LPS stimulation. Only 0.4% of the metabolites were significantly different between macrophages derived from young and old mice in the unstimulated controls indicating that there were virtually no detectable age-associated metabolic differences in the steady state. Age-associated differences in metabolism after LPS stimulation were visualized using an OPLS-DA score plot (Fig. 2A). Old macrophages were essentially non-responsive to LPS stimulation as compared to the young. After 4 hrs of LPS stimulation metabolic changes were apparent between young and old macrophages, and these became more distinct after 16 hrs of LPS stimulation. Unlike LPS stimulated young macrophages where approximately half of the metabolome was altered, only 2.2% (46/2125) and 13.3% (282/2125) of the features were altered in the old macrophages after 4 hrs and 16 hrs of LPS stimulation, respectively. There were however, 10.0% (211/2125) of the metabolic features were significantly changed with similar magnitude in both young and old macrophages after 16 hrs of LPS stimulation. Metabolites that were found to be increased in both young and old macrophages after 16 hrs of LPS stimulation included pantothenic acid, UDP-GlcNAc, N-acetyl-phenylalanine, PEs and almost half of detectable PCs. Overall, metabolic responses to LPS stimulation decrease with age.

Macrophages from old mice have defects in core metabolism during LPS stimulation. Macrophages switch their core metabolism from oxidative phosphorylation to glycolysis when stimulated with LPS. To examine whether the core metabolism of activated macrophages was affected by age, we designed a targeted metabolomics approach including in intermediates in glycolysis, the TCA cycle, the GABA shunt, the aspartate-argininosuccinate shunt and the urea cycle.

After 4 hrs of LPS stimulation, metabolites associated with the TCA cycle including oxaloacetate, malate, fumarate, succinate, α-ketoglutarate, citrate and glutamate were increased in macrophages from young mice (Figs S2A and S3A). After 16 hrs of LPS stimulation, the above-named metabolites remained elevated, and in addition, fructose-6-phosphate, lactate, GABA, arginine and ornithine also increased compared to the unstimulated control (Fig. 4A). In contrast, very few changes in this core metabolic pathway were noted in macrophages from old mice.
mice after LPS stimulation. Isocitrate, 2-phosphoglycerate (2PG) and 3PG were only decreased in the old macrophages after 4 hrs of LPS stimulation, and after 16 hrs of LPS stimulation, only arginine, malate, aspartate and GABA were increased (Fig. 5A, S2B, S3B). Decreased glucose-1-phosphate was observed in macrophages from both young and old mice after 4 and 16 hrs of LPS stimulation.

**Metabolic changes during LPS tolerance.** To examine the metabolic response associated with LPS tolerance in macrophages, we analyzed the metabolome of macrophages stimulated with a second dose of LPS for 4 hrs (“tolerance”). As a control, after 16 hrs of LPS stimulation, the cells were washed and cultured in LPS-free medium for 6 hrs (“recovery”). As visualized by the OPLS-DA score plot, the “recovery” and “tolerance” metabolic profiles from young mice resembled the early stage of LPS stimulation (Fig. 1C). In contrast, these profiles from old macrophages were distinct from 4 and 16 hrs of LPS stimulation (Fig. 1D).
We confirmed the LPS tolerance by quantifying transcripts that were known to be associated with the LPS tolerance (Fig. S4). Some metabolic changes appeared to be reversible when LPS was removed, whereas others were irreversible. Reversible metabolites were induced upon the first LPS stimulation but whose levels returned to baseline after LPS were removed. Reversible metabolites did not change expression levels after the LPS re-stimulation, however. Irreversible metabolites were induced upon primary LPS stimulation and remained elevated during the LPS re-stimulation. There are also a unique set of metabolites that were elevated during LPS re-stimulation, although the magnitude of induction during LPS re-stimulation was much lower compared to after the 16 hr of LPS stimulation. Conversely, for macrophages from old mice, 6% (128/2125) of the metabolic features were irreversible, 7.2% (154/2125) were reversible, and 6.8% (145/2125) of the features were significantly different in the tolerance group. Interestingly, arginine, ornithine, UDP-GlcNAc, UDP-G, ornithine, glutamine, and hypotaurine, which were only elevated in the young macrophages after 4 and 16 hrs of LPS stimulation, were found elevated in the “recovery” and “tolerance” groups of the old macrophages. This suggests that the metabolic responses to LPS stimulation are delayed in old macrophages.

Figure 2. The comprehensive analyses of bone marrow-derived macrophage extracts acquired using HILIC-TOF-MS. The ionization responses of 2125 intracellular metabolite features were normalized using IS. Extracts were performed in sextuplicate with three biological replicates and two culture replicates. (A) OPLS-DA score plot comparing the metabolic profiles of control (0 hr), 4 hr and 16 hr LPS stimulated macrophage extracts from both young and old mice. (B) Heat map visualization of the intracellular metabolite changes of macrophages of young and old mice in response to LPS stimulation. The 920 significant metabolite features (p < 0.05 one-way ANOVA, fold change greater than 1.5 compared to control) are represented in rows, and the experimental conditions were listed in columns. The heat map is plotted based on log2(fold change) with respect to the average levels of each metabolite feature in the control of macromolecules from young mice using Euclidean distance and complete-linkage clustering. OPLS-DA score plot comparing the metabolic profiles of control (0 hr), 4 hr, and 16 hr LPS stimulated macrophage extracts as well as “recovery” and “tolerance” treated macrophage extracts from (C) young or (D) old mice. Controls 1 and 2 obtained at the beginning (t = 0 hr) and the end of the experiments (t = 22 hrs) were considered as a single group. Samples belonging to the same treatment group were highlighted by open circles.
Similar trends were also observed for metabolites associated with macrophage core metabolism. In young macrophages, almost all of the metabolites that were elevated after 16 hrs of LPS stimulation were still elevated in the "recovery" and "tolerance" conditions for macrophages of both young and old mice. These included citrate, oxaloacetate, malate, fumarate, succinate, α-ketoglutarate, arginine, ornithine, glutamate and glutamine. Only GABA and lactate decreased to the levels observed in unstimulated macrophages. Interestingly, proline levels did not increase during LPS stimulation, but increased in the "recovery" group. Intermediates of the glycolysis pathway including isocitrate and glycolysis intermediates such as glucose-6-phosphate (G6P), fructose-6-phosphate (F6P), 3PG and 2PG were induced only after secondary LPS exposure in the young macrophages. Metabolic responses to LPS were delayed in the old macrophages. Metabolites such as oxaloacetate, fumarate, glutamine, arginine and ornithine were only increased in old macrophages after 16 hrs of LPS stimulation and in both the "recovery" and "tolerance" macrophages.

**Age-associated changes in arginine metabolism.** Macrophage polarization requires arginine metabolism via the urea cycle. The urea cycle intermediates, arginine and ornithine, were increased in the young macrophages after 16 hrs of LPS stimulation (Fig. 4). The levels of arginine and ornithine remained elevated in the young macrophages when LPS was removed and also during LPS tolerance. Similar to changes observed in macrophage core metabolism, there was a delay in arginine metabolism in old macrophages. Increasing levels of arginine and ornithine were only observed during the "recovery" and "tolerance" samples (Fig. 5).

The gene expression of Arg1, iNOS (Nos2) and the cationic amino acid transport (Slc7a2) were quantified. The expression of Arg1 and iNOS were elevated but not statistically different between LPS stimulated macrophages from young and old mice. Only Slc7a2 was differentially expressed between young and old macrophages after 16 hrs of LPS exposure, for which the expression of Slc7a2 in young macrophages was 1.43-fold greater than the old (Fig. 3E–H).

**Discussion**

LPS stimulation triggers a shift in macrophage core metabolism from oxidative phosphorylation to glycolysis. Glycolysis occurs in the cytoplasm and produces two ATPs per glucose. The end product of glycolysis, pyruvate, enters the mitochondria and initiates the TCA cycle and oxidative phosphorylation and results in the production of an additional 36 ATPs under aerobic conditions. Under anaerobic conditions, pyruvate is reduced to lactate in the cytoplasm and secreted. Although only 5% of the glucose's energy potential is taken advantage of during glycolysis, it can produce ATP at a much faster rate than oxidative phosphorylation. In addition to glucose metabolism, glutamine contributes to a third of the energy requirement of unstimulated macrophages via glutamine anaplerosis. The metabolic switch to glycolysis during LPS stimulation is a rapid way to accommodate the increased energy demand during inflammation. As macrophages shift from using oxidative phosphorylation to glycolysis, lactate and TCA intermediates such as malate, citrate and fumarate are increased intracellularly. Consistent with this, we have observed increasing levels of those metabolites in young macrophages after 16 hrs of LPS stimulation.

Macrophage specific adaptation of the TCA cycle has been reported. Jha et al. have reported that in macrophages, the metabolic flow between isocitrate and α-ketoglutarate is disrupted due to M1 macrophage specific metabolic break-point in the TCA cycle. Consistent with this result, in young macrophages, we also observed...
Figure 4. The enrichment map of glycolysis, the TCA cycle, the GABA shunt, and the urea cycle intermediates in bone marrow-derived macrophages from young mice in response to (A) 16 hr LPS stimulation, (B) “recovery”, and (C) “tolerance” as compared to unstimulated macrophages. The network of metabolite interactions was built based on the BioCyc database and pathway published from Jha et al.\textsuperscript{25}. The node size is proportional to the significance of metabolite changes compared to the control. The colors of the nodes indicate the log₂(fold changes) of metabolite levels of each experimental condition compared to the control with a decrease colored in red and an increase colored in blue. Acetyl-CoA, succinyl-CoA and succinic semialdehyde are not detected and therefore are labelled in grey. The glycolysis pathway is labelled in orange; the TCA cycle is labelled in blue; the GABA shunt is labelled in green; the glutamate-argininosuccinate shunt is labelled in red; the urea cycle is labelled in purple.
Figure 5. The enrichment map of glycolysis, the TCA cycle, the GABA shunt, and the urea cycle intermediates in bone marrow-derived macrophages from old mice in response to (A) 16 hr LPS stimulation, (B) "recovery", and (C) "tolerance" as compared to unstimulated macrophages. The network of metabolite interactions was built based on the BioCyc database and pathway published from Jha et al. The node size is proportional to the significance of metabolite changes compared to the control. The colors of the nodes indicate the log2(fold changes) of metabolite levels of each experimental condition compared to the control with a decrease colored in red and an increase colored in blue. Acetyl-CoA, succinyl-CoA and succinic semialdehyde are not detected and therefore are labelled in grey. The glycolysis pathway is labelled in orange; the TCA cycle is labelled in blue; the GABA shunt is labelled in green; the glutamate-argininosuccinate shunt is labelled in red; the urea cycle is labelled in purple.
a metabolic break in the TCA cycle between citrate and \(\alpha\)-ketoglutarate where, despite a global increase of almost all the TCA cycle intermediates, isocitrate remained unchanged after 16 hrs of LPS stimulation. Since we also observed this in our model of inflammation, this break-point in the TCA cycle may not be specific to M1 phenotypes but rather an indication of energy metabolism during inflammation. We did not observe the citrate/\(\alpha\)-ketoglutarate metabolic break in old macrophages because the TCA cycle remained effectively unchanged after LPS stimulation.

In the macrophages from old mice, the core metabolism was mostly unchanged in response to LPS stimulation, suggesting that mitochondrial function may be impaired. Mitochondrial dysfunction during aging is well documented\(^8\). Although mitochondrial metabolic dysfunction has not been thoroughly studied in macrophages, several studies of mitochondria from muscle tissues have shown reduced rates of glycolysis and the TCA cycle with age\(^27,28\). We did not detect increasing levels of lactate, malate, fumarate and citrate in LPS stimulated macrophages from old mice, consistent with mitochondrial dysfunction and an inability to shift from oxidative phosphorylation to glycolysis.

Interestingly, succinate was the only TCA cycle intermediate that was elevated in macrophages from both young and old mice in response to LPS stimulation (3.58- and 2.73- fold change at 16 hrs LPS respectively). Elevated succinate in response to LPS stimulation has been shown to stabilize hypoxia-inducible factor-1\(\alpha\) (HIF-1\(\alpha\)), a transcription factor that is required for IL-1\(\beta\) production\(^12\). IL-1\(\beta\) is a key inflammatory cytokine produced by macrophages during inflammatory responses. The induction of glutamine anaplerosis and the GABA shunt pathways are the principle source of succinate\(^15\). In young macrophages, we have observed consistently elevated levels of GABA (2.37-fold), glutamate (2.38-fold) and glutamine (2.66-fold) that fed into succinate production. In contrast, only GABA (2.70-fold) was increased in old macrophages after LPS stimulation. Although there are conflicting reports as to whether old macrophages produce more or less inflammatory cytokines in response to LPS\(^11,29\), our data imply succinate and its biosynthetic pathway would not be a rate limiting factor in generating an inflammatory response.

Arginine is required for macrophage activation\(^22\). Elevated levels of arginine and ornithine were observed in young but not old macrophages following 16 hrs of LPS stimulation. Intracellular arginine is mostly imported from the extracellular environment via cationic amino acid transport (CAT) in both humans and mice\(^30,31\). Of all the genes encoding the CAT, Slc7a2 is the only gene whose expression is inducible and is required during both M1 and M2 macrophage polarization\(^11,12\). We have observed a 30% reduction in Slc7a2 expression in the old macrophages compared to the young after 16 hrs of LPS stimulation, which likely contributes to the lower intracellular arginine level in the old macrophages. Arginine may also be synthesized via the aspartate-argininosuccinate shunt, which joins the TCA cycle with the urea cycle\(^26\). Inhibition of the aspartate-argininosuccinate shunt inhibits M1 polarization with low iNOS expression and nitric oxide production\(^25\). However, in our study, 16 hrs of LPS stimulation did not affect the aspartate-argininosuccinate shunt (i.e. aspartate, argininosuccinate) in macrophages from both young and old mice. Therefore, the aspartate-argininosuccinate shunt is unlikely to contribute to the increase of intracellular arginine in activated macrophages.

Metabolism of arginine via Arg1 or iNOS in the urea cycle regulates macrophage polarization\(^18\) M1 macrophages express iNOS which metabolizes arginine to nitric oxide to prevent pathogen infection by limiting free arginine and producing nitric oxide, a powerful antimicrobial agent. M2 macrophages express Arg1 which hydrolyzes arginine to ornithine to stimulate cell division and tissue repair through the production of polyamines and proline. LPS is known to induce both Arg1 and iNOS\(^9\), which we have also observed in LPS stimulated macrophages from young and old mice. Gene expression of Arg1 and iNOS were measured to further characterize the role of the urea cycle in age (Fig. 3H). Consistent with our data, there were no age-associated changes in iNOS or Arg1 expression in bone marrow-derived macrophages; however, others have reported decreased expression in LPS stimulated splenic and peritoneal murine macrophages\(^31\). Therefore, arginine metabolism is unlikely to be the rate limiting factor in the LPS response of old macrophages.

Dysregulation of LPS tolerance has been proposed as a contributing factor to the increased susceptibility of the elderly to sepsis and inflammatory disorders\(^13\). To test whether macrophages from old mice have defects in LPS tolerance, we measured a well-defined set of pro-inflammatory and anti-microbial genes associated with this phenomenon\(^12\). Both the young and old macrophages experienced LPS tolerance equally at the transcriptional level. However, our data demonstrated that there were metabolic changes specific to LPS tolerance. In the young macrophages, lactate levels were increased after the initial LPS stimulation, but returned to baseline levels when LPS was removed and did not increase during the second LPS stimulation. This indicated that the core metabolism of young macrophages did not shift from oxidative phosphorylation to glycolysis during LPS tolerance. This inability to adjust macrophage core metabolism to during LPS tolerance may be compensated for by up-regulation of glycolysis as indicated by the elevated levels of glycolysis intermediates. The inability to switch from glycolysis to oxidative phosphorylation may be a key metabolic break in LPS tolerance. In contrast to young macrophages, old macrophages did not shift from oxidative phosphorylation to glycolysis in either the first or second LPS stimulation. Moreover, elevated levels of arginine and TCA cycle intermediates were detected in both the first and second LPS stimulation in the young macrophages. In old macrophages, those metabolites were only induced much later, indicating that the old macrophages had a delayed metabolic response to LPS stimulation. Whether this delay is because of age-associated deterioration in mitochondria function, and specifically ATP production from glucose, is worth future investigation.

Adenosine is a “retaliatory metabolite” whose intracellular level is amplified at sites of injury and inflammation, and also mediates the resolution of inflammation by limiting tissue destruction\(^44\). Utilization of ATP during macrophage activation as a result of high metabolic activity leads to increased levels of intracellular adenosine\(^35\). Moreover, elevated levels of adenosine are known to enhance glycolysis and ATP production that supports metabolism in activated macrophages\(^42\). When adenosine is expressed in excess, it binds to adenosine receptors to suppress inflammatory responses, which preserves tissue homeostasis and prevents tissue damage\(^35\). Preventing
adrenosine breakdown by inhibiting adenosine deaminase reduces systemic inflammation such as sepsis. We observed increasing intracellular levels of adenosine and its precursor, adenosine, after LPS stimulation in young macrophages. Young macrophages reduced the expression of adenosine and adenosine to the baseline level of unstimulated macrophages during LPS tolerance. In contrast, levels of adenosine and adenosine were not changed during LPS stimulation or tolerance in old macrophages. This might be a result of the decreased metabolic activity and reduced rate of glycolysis in old macrophages.

Overall, age-associated metabolic dysfunction was observed in bone marrow-derived macrophages after LPS stimulation and during LPS tolerance. Inflammatory responses are energetically costly and result in high metabolic activity. For example, a 1 °C to 4 °C rise in core body temperature during fever helps to resolve bacterial and viral infections, and a 1 °C increase in temperature demands a 10–12.5% increase in metabolic rate. However, fever responses are often absent or blunted in the elderly and, rapid muscle wasting to sustain the high energy demand is common. We have observed metabolic bottlenecks between the switch from oxidative phosphorylation to glycolysis, which might contribute to impaired LPS-induced inflammation in the elderly. Moreover, the elderly are more vulnerable to nutrient deficiencies, such as arginine. Low arginine can attribute to the retarded immune function and is associated to poor health outcomes in the elderly. We found old macrophages are unable to adjust intracellular arginine level in response to LPS stimulation, but whether this is associated with arginine-related immune deficiencies is not known. In this study, metabolic bottlenecks were observed for macrophages from old mice during LPS stimulated inflammatory events, and metabolic dysregulation should be considered as a possible mechanism for declining immune function with age.

Experimental procedures

Bone marrow-derived macrophage culture. Bone marrow progenitors were collected from the femurs and tibia of young (6–8 wk) and old (18–22 mo) C57BL/6 mice (The Jackson Laboratory, Maine, USA). Progenitor cells were cultured for seven days in RPMI-1640 supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine, 1% penicillin/streptomycin and 15% L929 fibroblast cell conditioned medium on 150 mm Petri dish (Fisherbrand) as per standard protocols. On day 8, bone marrow-derived macrophages were counted and seeded into 24-well tissue-culture-treated plates (Falcon) and incubated overnight. For metabolomic studies, three biological replicates were performed. For each biological replicate, 3 × 105 macrophages were seeded per well in 1 mL RPMI-1640 with two culture replicates per mouse (n = 6 per treatment). For gene expression study, three biological replicates were performed. For each biological replicate, 1 × 10⁶ macrophages were seeded per well in 3 mL RPMI-1640 (n = 3 per treatment). All animal studies were approved by and performed in accordance with McMaster’s Animal Research Ethics Board.

Macrophage LPS stimulation. Macrophage LPS stimulation. Macrophages from both young and old mice were divided into six treatment groups. Groups 1 and 2 were stimulated with 100 ng/mL of bacterial lipopolysaccharide (LPS, Ultrapure LPS, *E. coli* 0111:B4 from Invivogen) in RPMI-1640 for 4 and 16 hrs respectively. Group 3 (“tolerance”) was incubated for 16 hrs with an initial LPS challenge (100 ng/mL), washed in PBS, incubated in regular RPMI-1640 for 2 hrs, and then re-stimulated with 100 ng/mL of LPS for 4 hrs. Group 4 (“recovery”) was incubated for 16 hrs with LPS (100 ng/mL), washed in PBS, incubated in regular RPMI-1640 for 6 hrs. Group 5 and 6 were controls that were cultured in regular RPMI-1640 for 0 and 22 hrs. The experimental protocol for LPS tolerance study was based on Foster et al. All cells were washed once with cold phosphate-buffered saline (PBS) and collected for metabolomic and gene expression studies.

Macrophage extraction for metabolomic analyses. After macrophages were washed with 1 mL of cold PBS, the cells were detached from the 24-well plate using a cell lifter in the presence of cold extraction solvent mixture methanol/ethanol/H₂O (200 μL, 2:2:1, v/v) containing standards for recovery determination (98% L-methionine-d₃, 98% L-tryptophan-d₅) as the cell suspension was transferred into a 1.5 mL microtube (Diamed, ON, Canada) and vortex mixed for 2 min in the presence of two 2 mm ball bearings. After removal of the bearings, the mixture was centrifuged at 9500 × g for 3 min at 4 °C. The supernatant was collected and the precipitated pellet (containing DNA, RNA, and proteins) was re-extracted twice with cold methanol/ethanol/H₂O (50 μL) as with above. Cell extract (150 μL) was dried under nitrogen gas and re-solubilized in 60%v/v ACN/H₂O containing standards (50 μL, 98% L-phenylalanine-d₆, diphenylalanine, glycine-phenylalanine) for peak area normalization (IS) for LC-MS analysis. A quality control pooled sample was prepared by combining ACN/H₂O macrophage extracts (5 μL) from a total of 72 samples of all treatment groups.

For GC-MS analysis, 20 μL of the ACN/H₂O macrophage extract or pooled samples was dried under nitrogen gas, and reconstituted in 25 μL of 1%v/v chlorotrimethylsilane (TMCS) in N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) and 5 μL of acetonitrile and trimethylsilyl trifluoroacetamide (ISM for GC-MS) in toluene (1.2 ng/μL). The samples were incubated at 60 °C for 1 hr and analyzed by GC-MS immediately.

The entire sample preparation procedure was performed on ice or in a cold room. The sample extracts were stored in a −80 °C freezer prior to analyses.

LC-HILIC-TOF-MS comprehensive analysis. Macrophage extracts were analyzed using an Agilent Technologies Model 1200RR series II liquid chromatograph coupled to a Bruker microTOF II Mass Analyzer as previously described. A Phenomenex Kinetix 2.6 μm core shell HILIC column (2.1 × 50 mm, pore size 100 Å) was operated at 200 μL/min using a linear gradient of acetonitrile (A) and 10 mM ammonium acetate, adjusted to pH 3 (B). The column temperature was maintained at 40 °C, and the auto sampler storage tray was set at 4 °C. LC gradient: 0–0.5 min, 95% A; 0.5–12.5 min, 95% A to 35% A; hold at 35% A for 0.5 min; 35% A to 95% A over 1 min; re-equilibration at 95% A for 10 min prior to the next injection. A 2 μL sample was injected to a total run
time of 24 min for both positive and negative electrospray ionization (ESI) modes. The mass spectrometer setting was identical to those previously reported in Fei et al.43.

**GC-MS targeted analysis.** GC-MS analyses were performed using an Agilent 6890 N gas chromatograph (Santa Clara, CA, USA), equipped with a DB-17ht column (30 m × 0.25 mm i.d. × 0.15 μm film, J & W Scientific) and a retention gap (deactivated fused silica, 5 m × 0.53 mm i.d.), and coupled to an Agilent 5973 MSD single quadruple mass spectrometer. The autosampler storage tray was maintained below 5°C with a cooler system. The derivatized macrophage extract (1 μL) was injected using Agilent 7683 autosampler in splitless mode. The injector temperature was 230°C and carrier gas (helium) flow was 0.8 mL/min. The transfer line was 280°C and the MS source temperature was 230°C. The column temperature was set at 70°C for 0.1 min, raised to 225°C at 5°C/min, and then 310°C at 55°C/min and held there for 4 min. After a five minute solvent delay, mass spectra were acquired using electron ionization (EI) with a selected-ion-monitoring (SIM) mode as in Table S2. Metabolic intermediates of glycolysis, TCA, aspartate-argininosuccinate shunt, GABA shunt and urea cycle were included in this study (Table S1).

**Quality Control.** For both LC-MS and GC-MS metabolomic analyses, pooled samples were run 7 times to condition the column prior to sample analysis and also run after every 5th sample. MeOH/EtOH/H2O blank and a retention gap (deactivated fused silica, 5 m × 0.53 mm i.d.) were also run after every 5th sample. MeOH/EtOH/H2O blank and a retention gap (deactivated fused silica, 5 m × 0.53 mm i.d.), and coupled to an Agilent 5973 MSD single quadruple mass spectrometer. The autosampler storage tray was maintained below 5°C with a cooler system. The derivatized macrophage extract (1 μL) was injected using Agilent 7683 autosampler in splitless mode. The injector temperature was 230°C and carrier gas (helium) flow was 0.8 mL/min. The transfer line was 280°C and the MS source temperature was 230°C. The column temperature was set at 70°C for 0.1 min, raised to 225°C at 5°C/min, and then 310°C at 55°C/min and held there for 4 min. After a five minute solvent delay, mass spectra were acquired using electron ionization (EI) with a selected-ion-monitoring (SIM) mode as in Table S2. Metabolic intermediates of glycolysis, TCA, aspartate-argininosuccinate shunt, GABA shunt and urea cycle were included in this study (Table S1).

**Data Analyses and metabolite identification.** The comprehensive LC-MS data were processed as in Fei et al.43. The LC-MS spectra were converted to .mzXML format using Bruker CompassXport followed by internal mass calibration using sodium formate cluster in both ESI+ and ESI− modes by Bruker's DataAnalysis 4.0 SP4. The metabolite features were extracted and aligned using open source XCMS with centWave algorithm (minfrac = 0.8)43; adducts, isotopic ions, and in-source fragments were identified using CAMERA46. The metabolite features were normalized with IS eluted closest to their retention time (i.e. features eluted before 6.50 min were normalized by phe-phe; features eluted between 6.50 and 7.80 min were normalized by L-phenylalanine-d8; features eluted after 7.80 min were normalized by gly-phe). After data reduction, the final data set was composed of 2125 metabolic features (Table S4).

The metabolite features were identified by matching the mass-to-charge (m/z) and the retention time of authentic standards or compound analogs (for phospholipid identification only). There were 150 features identified to 121 metabolites in the final data set, 57 were polar metabolites and 64 were phospholipids. One metabolite could have multiple metabolic features resulting from adducts or in-source fragments.

For the GC-MS dataset, peak detection and spectrum deconvolution were processed using Agilent's Enhanced ChemStation. Multiple peaks generated from direct derivitization of a single metabolite were combined. The peak area of metabolites was normalized to anthracenemethanol. The final data sets for comprehensive LC-MS and targeted GC-MS analyses are included in supplementary material 2.

**Statistical Analyses.** The final set of comprehensive LC-MS analysis was analyzed using multivariate analysis including principal component analysis (PCA) and OPLS-DA after pareto scaling by SIMCA-P + 12.0.1 (Umetrics, Umeå, Sweden). The normality of both LC-MS and GC-MS data were analyzed using Kolmogorov-Smirnov test by SPSS 20 (SPSS, Chicago, IL, USA). Both LC-MS and GC-MS data were analyzed with univariate statistical tool including Student's t test (two-tailed, unpaired heteroscedastic) and one-way ANOVA by Microsoft Excel 2010 and MetaboAnalyst 3.0, respectively. Metabolic features or metabolites with p value less than 0.05 and fold change greater than 1.5 between treatment groups were considered significantly differentiated. Heatmap was generated with R Project 2.12.2 using gplots.

**References**

1. Nathan, C. Points of control in inflammation. *Nature* **420**, 846–852 (2002).
2. Solana, R., Pawelec, G. & Tarazona, R. Aging and innate immunity. *Immunity* **24**, 491–494 (2006).
3. Weng, N.-P. Aging of the immune system: how much can the adaptive immune system adapt? *Immunity* **24**, 495–499 (2006).
4. Gomez, C. R., Boehmer, E. D. & Kovacs, E. J. The aging innate immune system. *Curr. Opin. Immunol.* **17**, 457–462 (2005).
5. Weiskopf, D., Weinberger, B. & Grubeck-Loeberstein, B. The aging of the immune system. *Transpl. Int.* **22**, 1041–1050 (2009).
6. Ginaldi, L., Loreto, M. F., Corsi, M. P., Modesti, M. & De Martinis, M. Immunosenescence and infectious diseases. *Microbes. Infect.* **3**, 851–857 (2001).
7. Franceschi, C. et al. Inflamm-aging: An evolutionary perspective on immunosenescence. *Ann. N. Y. Acad. Sci.* **908**, 244–254 (2000).
8. Gordon, S. & Taylor, P. R. Monocyte and macrophage heterogeneity. *Nat. Rev. Immunol.* **5**, 953–964 (2005).
9. Murray, P. J. et al. Macrophage activation and polarization: nomenclature and experimental guidelines. *Immunity* **41**, 14–20 (2014).
Author Contributions
B.E.M. and D.M.E.B. conceived the study. F.F., B.E.M. and D.M.E.B. designed the study. K.M.L. cultured infectious disease research (IIDR). F.F. is supported by Ontario Graduate Scholarship (OGS). D.M.E.B. is supported by the CIHR and holds a Canada Research Chair. Work in the Bowdish laboratory is supported by the McMaster Immunology Research Centre (MIRC) and M.G. DeGroote Institute for Infectious Disease Research (IIDR). FF is supported by Ontario Graduate Scholarship (OGS).

Acknowledgements
This work was dedicated to late Prof. Brian McCarty (1946–2013). We like to thank Dr. M. Kirk Green for insightful discussion and Center for Microbial Chemical Biology (CMCB) for the access to the LC-MS instrumentation. DMEB is supported by the CIHR and holds a Canada Research Chair. Work in the Bowdish laboratory is supported by the McMaster Immunology Research Centre (MIRC) and M.G. DeGroote Institute for Infectious Disease Research (IIDR). FF is supported by Ontario Graduate Scholarship (OGS).

10. Plowden, J., Renshaw-Hoelscher, M., Engleman, C., Katz, J. & Sambaroa, S. Innate immunity in aging: impact on macrophage function. Aging cell 3, 161–167 (2004).
11. Mahbub, S., Deburgobraege, C. R. & Kovacs, E. J. Advanced Age Impairs Macrophage Polarization. J. Interferon Cytokine Res. 32, 18–26 (2012).
12. Foster, S. L., Hargreaves, D. C. & Medzhitov, R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 447, 972–978 (2007).
13. Cavaillon, J.-M. & Adib-Conquy, M. Bench-to-bedsite review: Endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit. Care 10, 233 (2006).
14. Sun, Y. et al. Effects of aging on endotoxin tolerance induced by lipopolysaccharides derived from Porphyromonas gingivalis and Escherichia coli. PLoS one 7, e39224 (2012).
15. Rodriguez-Prados, J.-C. et al. Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation. J. Immunol. 185, 605–614 (2010).
16. Sugimoto, M. et al. Non-targeted metabolite profiling in activated macrophage secrretion. Metabolomics 8, 624–633 (2011).
17. Tannanhill, G. M. et al. Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature 496, 238–242 (2013).
18. Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J. & Hill, A. M. M-1/M-2 Macrophages and the Th1/Th2 Paradigm 1. J. Immunol. 164, 6166–6173 (2000).
19. Haskó, G. & Cronestein, B. N. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 25, 33–39 (2004).
20. Houtkooper, R. H. et al. The metabolic footprint of aging in mice. Sci. Rep. 1, 134 (2011).
21. Yu, Z. et al. Human serum metabolic profiles are age dependent. Aging cell 11, 960–967 (2012).
22. Hibbs, J. B. Jr, Varvin, Z. & Taintor, R. R. I.-Arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J. Immunol. 138, 550–563 (1987).
23. Zheng, J. Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation. Oncol. Lett. 4, 1115–1157 (2012).
24. Newsolme, P. et al. Glutamine metabolism by lymphocytes, macrophages and neutrophils: Its importance in health and disease. J. Nutr. Biochem. 10, 316–324 (1999).
25. Jha, A. K. et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity 42, 419–430 (2015).
26. Green, D. R., Galluzzi, L. & Kroemer, G. Mitochondria and the Autophage-inflammation-cell death axis in organismal aging. Science 333, 1109–1112 (2011).
27. Kaczor, J. J. et al. The effect of aging on anaerobic and aerobic enzyme activities in human skeletal muscle. J. Gerontol. A. Biol. Sci. Med. Sci. 61, 339–344 (2006).
28. Lee, C.-K., Klopp, R. G., Weindruch, R. & Prolla, T. A. Gene expression profile of aging and its retardation by caloric restriction. J. Biol. Chem. 286, 19247–19258 (2011).
29. Kohut, M. L. et al. Age effects on macrophage function vary by tissue site, nature of stimulant, and exercise behavior. Exp. Gerontol. 39, 1347–1360 (2004).
30. Bogle, R. G., Baydoun, A. R., Pearson, J. D., Moncada, S. & Mann, G. E. I.-Arginine transport is increased in macrophages generating nitric oxide. Biochem. J. 284, 15–18 (1992).
31. Kurok, J. et al. Dysfunction in macrophage toll-like receptor signaling caused by an inborn error of cationic amino acid transport. Mol. Immunol. 46, 416–425 (2015).
32. Veramian, A. et al. Arginine transport via cationic amino acid transporter 2 plays a critical regulatory role in classical or alternative activation of macrophages. J. Immunol. 176, 5918–5924 (2006).
33. Ruiz-Garcia, A. et al. Cooperation of adenosine with macrophage Toll-4 receptor agonists leads to increased glycolytic flux through the enhanced expression of PFKFB3 gene. J. Biol. Chem. 286, 19247–19258 (2011).
34. Adanin, S. et al. Inhibiting adenosine deaminase modulates the systemic inflammatory response syndrome in endotoxemia and sepsis. Am. J. Physiol. Regulatory Integrative Comp. Physiol 282, R1324–R1332 (2002).
35. Hotamisligil, G. S. & Erbay, E. Nutrient sensing and inflammation in metabolic diseases. Nat. Rev. Immunol. 8, 923–934 (2008).
36. Evans, S. S., Repasky, E. a. & Fisher, D. T. Fever and the thermal regulation of immunity: the immune system feels the heat. Nat. Rev. Immunol. 15, 335–349 (2015).
37. Norman, D. C. Fever in the elderly. Infect. Dis. Clin. North. Am. 10, 148–151 (1996).
38. Lochmiller, R. L. & Deerenberg, C. Trade-offs in evolutionary immunology: just what is the cost of immunity? OIKOS 88, 87–98 (2000).
39. Brownie, S. Why are elderly individuals at risk of nutritional deficiency? Int. J. Nurs. Pract. 12, 110–118 (2006).
40. Hursom, M., Regan, M. C., Kirk, S. J., Wasserkrug, H. L. & Barbul. A. Metabolic effects of arginine in healthy elderly population. JPEN J. Parenter. Enteral. Nutr. 19, 227–230 (1995).
41. Davies, I. Q. & Gordon, S. Isolation and culture of murine macrophages. Methods Mol. Biol. 290, 91–103 (2005).
42. Weischenfeldt, J. & Porse, B. Bone marrow-derived macrophages (BMM): isolation and applications. CSH Protocol 3, 1–7 (2008).
43. Fei, F., Bowdish, D. M. E. & McCary, B. E. Comprehensive and simultaneous coverage of lipid and polar metabolites for endogenous cellular metabolomics using HILIC-TOP-MS. Anal. Bioanal. Chem. 406, 3732–3733 (2014).
44. Trappnell, C. et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 7, 562–578 (2012).
45. Smith, C. A., Want, E. J., O’Malley, G., Abagyan, R. & Siruzdak, G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal. Chem. 78, 779–787 (2006).
46. Kuhl, C., Tautenhahn, R. & Neumann, S. LC-MS Peak Annotation and Identification with CAMERA. 1–14 (2010).
**Additional Information**

**Supplementary information** accompanies this paper at http://www.nature.com/srep

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Fei, F. et al. Age-associated metabolic dysregulation in bone marrow-derived macrophages stimulated with lipopolysaccharide. Sci. Rep. 6, 22637; doi: 10.1038/srep22637 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/